1. Home
  2. LZ vs VIR Comparison

LZ vs VIR Comparison

Compare LZ & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LegalZoom.com Inc.

LZ

LegalZoom.com Inc.

N/A

Current Price

$10.13

Market Cap

1.8B

Sector

Technology

ML Signal

N/A

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

N/A

Current Price

$6.16

Market Cap

773.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LZ
VIR
Founded
2001
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
773.5M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
LZ
VIR
Price
$10.13
$6.16
Analyst Decision
Buy
Strong Buy
Analyst Count
7
11
Target Price
$11.50
$25.73
AVG Volume (30 Days)
1.8M
1.9M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.12
N/A
Revenue
$727,483,000.00
$16,860,000.00
Revenue This Year
$13.38
N/A
Revenue Next Year
$7.07
$48.05
P/E Ratio
$84.55
N/A
Revenue Growth
7.17
N/A
52 Week Low
$6.47
$4.16
52 Week High
$12.40
$14.45

Technical Indicators

Market Signals
Indicator
LZ
VIR
Relative Strength Index (RSI) 60.45 50.43
Support Level $9.28 $6.00
Resistance Level $10.40 $6.75
Average True Range (ATR) 0.26 0.46
MACD 0.11 -0.04
Stochastic Oscillator 80.48 49.07

Price Performance

Historical Comparison
LZ
VIR

About LZ LegalZoom.com Inc.

LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Share on Social Networks: